Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic abdominal pain in patients with small duct chronic pancreatitis in a superior fashion compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an increase in quality of life. Our objective is to elucidate the role of Nexium in the control of pancreatic pain, quality of life, and narcotic usage alone or when added to Viokase 16. Our endpoints are the reduction of abdominal pain, decreased pain medication usage, decreased ER visits and decreased hospital admissions for abdominal pain.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
one 40 mg capsule per day for one month
one capsule per day for one month
Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
University of Florida
Gainesville, Florida, United States
Reduction of Abdominal Pain for Participants Taking Nexium Alone.
To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
Time frame: 4 months
Reduction of Abdominal Pain for Participants Taking Placebo to Nexium
To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
Time frame: 4 months
Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Nexium
To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
Time frame: 4 months
Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Placebo.
To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month